Company intelligence / Profile preview

ATB Therapeutics

Marche-en-Famenne, Belgiumatbtherapeutics.com ↗

Ownership: Private
Employees: ~49
Development stage: Preclinical

Overview

ATB Therapeutics is developing novel antibody-based therapies using its proprietary ATBioFarm platform. The company is building a pipeline of weaponized antibodies that integrate novel cell-killing mechanisms within targeted antibodies.

Therapeutic areas: OncologyImmunology
Modalities: Antibody therapiesWeaponized antibodiesAntibody-toxin-bioengineered 'atbodies'
Industry: Biotech

Drug pipeline

1 asset

atbody

Preclinical

Beyond the preview

Go deeper on ATB Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATB Therapeutics.

Explore the full profile